Rowlett J K, Mattingly B A, Bardo M T
Department of Psychology, University of Kentucky, Lexington 40506-0044, USA.
Synapse. 1995 Jul;20(3):209-16. doi: 10.1002/syn.890200304.
Repeated treatment with the non-selective dopamine agonist apomorphine results in behavioral sensitization and enhanced dopamine synthesis in dopamine projection fields. To examine the role of D2-type dopamine receptors in modulating these effects, the present experiment assessed the effects of repeated treatment with the D2-type agonist quinpirole on locomotor activity and dopamine synthesis. In the first experiment, rats were treated with vehicle or one of two doses (0.3 or 3.0 mg/kg) of quinpirole for 8 days. Daily measures of locomotor activity revealed an initial suppression of activity produced by quinpirole which dissipated over the 8 days of treatment. A trend for an increase in activity for 3.0 mg/kg quinpirole compared to vehicle was obtained on day 8. Twenty-four hours after cessation of treatment, dopamine synthesis, measured as accumulation of 3,4-dihydroxyphenylalanine (DOPA) after treatment with the DOPA decarboxylase inhibitor NSD-1015, was enhanced in the striatum, but not nucleus accumbens-olfactory tubercle (NAOT) or ventral mesencephalon (VM). In Experiment 2, rats were treated for 8 days with vehicle, 3.0 mg/kg quinpirole or the D1 antagonist SCH 23390 (0.5 mg/kg) in a two (vehicle or quinpirole) x two (vehicle or SCH 23390) design. Quinpirole-alone treatment resulted in a reduction of the locomotor suppressant effects of the drug. SCH 23390-alone and quinpirole-SCH 23390 combined treatment resulted in decreased activity compared to the vehicle control group that did not change across days. DOPA accumulation was enhanced in the striatum and NAOT after quinpirole treatment; however, SCH 23390 had no effect.(ABSTRACT TRUNCATED AT 250 WORDS)
用非选择性多巴胺激动剂阿扑吗啡反复治疗会导致行为敏化,并增强多巴胺投射区域的多巴胺合成。为了研究D2型多巴胺受体在调节这些效应中的作用,本实验评估了用D2型激动剂喹吡罗反复治疗对运动活性和多巴胺合成的影响。在第一个实验中,大鼠用赋形剂或两种剂量(0.3或3.0毫克/千克)的喹吡罗之一治疗8天。每日运动活性测量显示,喹吡罗产生的活性最初受到抑制,这种抑制在8天的治疗过程中逐渐消失。在第8天,与赋形剂相比,3.0毫克/千克喹吡罗组的活性有增加的趋势。治疗停止24小时后,在用多巴脱羧酶抑制剂NSD - 1015治疗后,以3,4 - 二羟基苯丙氨酸(DOPA)的积累来衡量,纹状体中的多巴胺合成增强,但伏隔核 - 嗅结节(NAOT)或腹侧中脑(VM)中没有增强。在实验2中,大鼠在一个二(赋形剂或喹吡罗)×二(赋形剂或SCH 23390)设计中,用赋形剂、3.0毫克/千克喹吡罗或D1拮抗剂SCH 23390(0.5毫克/千克)治疗8天。单独使用喹吡罗治疗导致该药物的运动抑制作用减弱。与在各天中没有变化的赋形剂对照组相比,单独使用SCH 23390以及喹吡罗 - SCH 23390联合治疗导致活性降低。喹吡罗治疗后,纹状体和NAOT中的DOPA积累增强;然而,SCH 23390没有效果。(摘要截短为250字)